This message was sent to ##Email##
|
|
|
|
|
AST
The prize drawing for the 2018-2019 Member-Get-A-Member program is upcoming in June 2019! There is still time to enter to win - recommend your colleagues to join AST today! We’re making it easier for you to refer new members with our easy referral form. You can quickly send a personal and professional email message to refer your colleagues by clicking here (referral form).
For every new member successfully recruited, your name will be entered to win one of the following great prizes:
• iPad and one year free membership
• $500 AST bucks
• $250 AST bucks
New this year: Every member who successfully recruits 3 new members will receive one year of free membership!
Visit the Member-Get-A-Member page for program details and other resources.
AST
Join thousands of transplant professionals at this year’s American Transplant Congress (ATC), June 1-5, 2019, in Boston, MA. From cutting-edge science that’s transforming the field, to in-depth workshops and hot topic sessions, the ATC is quickly becoming the most recognized transplant Congress in the world. READ MORE
CMS
The Centers for Medicare & Medicaid Services (CMS) issued a final rule on May 16, 2019 that modernizes and improves the Medicare Advantage and Part D programs. These changes will ensure that patients have greater transparency into the cost of prescription drugs in Part D and will also enable Medicare Advantage plans to negotiate better prices for physician-administered medicines in Part C.
READ MORE
| . |
SPONSORED VIDEO |
Advertisement
|
 |
|
Promoted by
Veloxis Pharmaceuticals
Follow the journeys of kidney transplant patients who transitioned to a different immunosuppression regimen. After talking with their doctors about their experiences with other options, they decided to make a switch.
Watch video
|
|
AST
The AST Board of Directors election is now open. If you are an eligible member of the AST, check your email for information on how to vote. More information about the nominees can be found here.
AST
As an AST member, access to free or discounted educational resources are included in your membership. These diverse educational resources offer materials relevant to the transplant professional in every stage of their career – from basic trainee lessons to webinars on specialized topics. Learn More
Advertisement
Veloxis Pharmaceuticals
Explore this phase 3 randomized, double-blind, double-dummy, multicenter, multinational, non-inferiority trial published in the American Journal of Transplantation. The study examined treatment failures defined as BPAR, graft failure, death, and delayed graft function at 3 months and 12 months.
Explore data
|
AST
The Transplant Nephrology Core Curriculum (TNCC) is an online program jointly provided by the American Society of Nephrology and the American Society of Transplantation. The TNCC focuses on key information needed to prepare for the American Board of Internal Medicine Nephrology Board Certification and Maintenance of Certification examinations.
READ MORE
AST
Transplant professionals have increasing demands on their time. Finding time in one's day to attend conferences or to read journals is challenging. Transplant in 10 is intended to provide transplant professionals with short, easily accessible videos on key and updated topics in 10 minutes.
READ MORE
|
The first and only clinically and analytically validated blood test that measures donor-derived cell-free DNA (dd-cfDNA), a direct indicator of kidney injury
Covered by Medicare
AlloSure 101 – Development & Summary Webinar – view
|
|
|
|
|
|
The Enhanced LSA assay demonstrates a lower
false positive rate1
—increasing your ability to find
acceptable donors and providing new beginnings
for more transplant patients. With added coverage
and specificity, our test is designed for you, to
improve operational efficiencies and workflow.
Learn more
|
|
|
|
|
American Journal of Transplantation
Cohosts Josh Levitsky, MD, and Roslyn Mannon, MD, discuss the latest issues of the American Journal of Transplantation, summarizing Editors’ Picks by highlighting the key messages, broader impact, and take-home points of each article. The views are their own and do not necessarily reflect those of the journal or the Societies that support it. Available on iTunes, Google Play, Stitcher, and Podbean.
READ MORE
The New England Journal of Medicine
In the context of kidney transplantation, genomic incompatibilities between donor and recipient may lead to allosensitization against new antigens. We hypothesized that recessive inheritance of gene-disrupting variants may represent a risk factor for allograft rejection.
READ MORE
American Association for the Study of Liver Diseases via Wiley Online Library
In patients with hepatocellular cancer (HCC) meeting the Milan Criteria (MC), the benefit of loco‐regional treatments (LRT) in the context of liver transplantation (LT) is still debated. Initial biases in the selection between treated and untreated patients have yielded conflicting reported results.
READ MORE
|
|
American Association for the Study of Liver Diseases via Wiley Online Library
The prevalence and management of coronary artery disease (CAD) in liver transplantation (LT) candidates are not well characterized. The aims of this study were: (1) to evaluate the impact on clinical outcomes of a specifically designed protocol for the management of asymptomatic CAD in LT candidates and (2) to investigate non‐invasive risk profiles for obstructive and non‐obstructive CAD.
READ MORE
The Journal of Heart and Lung Transplantation
The new heart allocation system in the United States prioritizes patients supported by temporary mechanical circulatory support (TMCS) devices over those with uncomplicated durable continuous-flow left ventricular assist devices (CF-LVADs), which may increase the number of patients bridged to transplant with TMCS.
READ MORE
Journal for Immunotherapy of Cancer
Checkpoint inhibitors (CPIs) have revolutionized the treatment of cancer, but their use remains limited by off-target inflammatory and immune-related adverse events. Solid organ transplantation (SOT) recipients have been excluded from clinical trials owing to concerns about alloimmunity, organ rejection, and immunosuppressive therapy. Thus, we conducted a retrospective study and literature review to evaluate the safety of CPIs in patients with cancer and prior SOT.
READ MORE
|
The articles included in this email are for informational use only and are not endorsed by the AST.
|
|
|
|
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063
|
